The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 07, 2018
Filed:
Jun. 30, 2017
Applicant:
The Johns Hopkins University, Baltimore, MD (US);
Inventors:
Martin G. Pomper, Baltimore, MD (US);
Sangeeta Ray, Ellicott City, MD (US);
Ronnie C. Mease, Fairfax, VA (US);
Catherine Anne Foss, Baltimore, MD (US);
Assignee:
THE JOHNS HOPKINS UNIVERSITY, Baltimore, MD (US);
Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 51/04 (2006.01); A61K 31/195 (2006.01); C07D 257/00 (2006.01); G01N 33/60 (2006.01); C07F 13/00 (2006.01); C07D 257/02 (2006.01); C12Q 1/37 (2006.01); G01N 33/574 (2006.01); C07D 215/12 (2006.01); C07D 213/38 (2006.01); A61K 38/06 (2006.01); A61K 31/4402 (2006.01); A61K 31/395 (2006.01); A61K 31/145 (2006.01);
U.S. Cl.
CPC ...
A61K 51/0472 (2013.01); A61K 31/145 (2013.01); A61K 31/195 (2013.01); A61K 31/395 (2013.01); A61K 31/4402 (2013.01); A61K 38/06 (2013.01); C07D 213/38 (2013.01); C07D 215/12 (2013.01); C07D 257/00 (2013.01); C07D 257/02 (2013.01); C07F 13/00 (2013.01); C12Q 1/37 (2013.01); G01N 33/57434 (2013.01); G01N 33/60 (2013.01); G01N 2500/04 (2013.01);
Abstract
The prostate-specific membrane antigen (PSMA) is increasingly recognized as a viable target for imaging and therapy of cancer. Various 99mTc/Re-labeled compounds were prepared by attaching known Tc/Re chelating agents to an amino-functionalized PSMA inhibitor with or without a variable length linker moiety. Ex vivo biodistribution and in vivo imaging demonstrated the degree of specific binding to engineered PSMA+ PC3 PIP tumors.